loading...| Preferred Name |
pirfenidone |
|
| Synonyms |
Deskar |
|
| Definitions |
An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2635" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2635" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038334 |
|
| altLabel |
Deskar |
|
| CAS Registry |
53179-13-8 |
|
| cui |
C0298067 C0936003 |
|
| Date last modified |
2006-09-11 |
|
| definition |
An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2635" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2635" NCI Thesaurus) |
|
| Legacy PDQ ID |
10953 |
|
| NCI ID |
C2635 |
|
| notation |
CDR0000038334 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
pirfenidone |
|
| tui |
T109 T121 |